Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients

Leukemia volume 19, pages 1985–1987 (2005)Cite this article

TO THE EDITOR

Resistance to imatinib can arise through point mutations in the ABL kinase domain or BCR-ABL gene amplification (reviewed in Gambacorti-Passerini et al1), by activation of the efflux pumps2 or by other unknown mechanisms. Resistance to imatinib frequently develops in patients with advanced disease. In this setting, resistance develops within few months of treatment and imatinib dose increase has a rather limited impact.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.

    Article  Google Scholar 

  2. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368–2373.

    Article  CAS  Google Scholar 

  3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  4. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    Article  CAS  Google Scholar 

  5. Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.

    Article  CAS  Google Scholar 

  6. Kantarjian HM, Talpaz M, O’Brien S, Giles F, Garcia-Manero G, Faderl S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101: 473–475.

    Article  CAS  Google Scholar 

  7. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA . The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003; 9: 2092–2097.

    CAS  PubMed  Google Scholar 

  8. Marin D, Goldman JM, Olavarria E, Apperley JF . Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003; 102: 2702–2703; author reply 2703–2704.

    Article  CAS  Google Scholar 

  9. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  Google Scholar 

  10. Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L et al. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to imatinib. Leukemia 2005; 19: 132–134.

    Article  CAS  Google Scholar 

  11. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Edoardo Marchesi and Silvia Portincasa for editorial and technical support. Grants: This work was funded by AIRC, EU (LSHB-CT-2004-503467), Ric. Fin. 2003, MIUR-COFIN and PRIN programs (2003, 2004), CNR, CIHR, NCIC, CFI.

Author information

Authors and Affiliations

  1. Department of Experimental Oncology, National Cancer Institute, Milan, Italy

    R G Piazza, V Magistroni, F Andreoni & C Gambacorti-Passerini

  2. University of Milano Bicocca, S Gerardo Hospital, Monza, Italy

    R G Piazza & A Franceschino

  3. Section of Hematology, S Gerardo Hospital, Monza, Italy

    L Tornaghi, G Corneo, E M Pogliani & C Gambacorti-Passerini

  4. Cancer Center, University of Colorado Health Sciences Center, Denver, CO, USA

    M Varella-Garcia

  5. M Tettamanti Research Center, Pediatric Clinic, University of Milano Bicocca, Monza, Milan, Italy

    S Bungaro & F Colnaghi

  6. Department of Oncology, McGill University, Montreal, Canada

    C Gambacorti-Passerini

Authors
  1. R G Piazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Magistroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Andreoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Franceschino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Tornaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Varella-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Bungaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Colnaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Corneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E M Pogliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Gambacorti-Passerini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Gambacorti-Passerini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piazza, R., Magistroni, V., Andreoni, F. et al. Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia 19, 1985–1987 (2005). https://doi.org/10.1038/sj.leu.2403928

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403928

This article is cited by

Search

Advanced search

Quick links